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Summary Long-term outcome was reviewed in 266 consecutive patients with metastatic non-seminomatous
germ cell tumours treated at a single institution. The overall 3 year survival was 77%, and 3 year progression-
free survival was 71%. Multivariate analysis identified the following clinical features as independent prognostic
factors: the presence of liver, bone or brain metastasis, serum human chorionic gonadotropink10000 U 1-1
and/or alpha-fetoprotein > 1000 ng ml-1, a mediastinal mass>5 cm and the presence of 20 or more lung
metastases. Age was not ofprognostic significance. Patients without any ofthe above poor-risk factors had a 3-
year survival of 91% regardless of etoposide- or vinblastine-containing chemotherapy compared with 61% for
the remaining patients. However, etoposide-containing protocols led to significantly improved survival in
patients with at least one poor risk factor. After 612 patient-years of observation no case of secondary
leukaemia was observed among 119 surviving patients who had received etoposide as part of their treatment.
With a median follow-up of 93 months, five patients developed a second germ cell tumour, two patients non-
germ cell malignancies. Fourteen patients relapsed after a disease-free interval of more than 2 years, and nine
patients died more than 5 years after commencement of treatment underscoring the need to report long-term
results. There is some evidence that cumulative experience translates into improved survival and cure rates for
patients with poor-risk metastatic disease.
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Testicular cancer is the most common neoplasm in males
aged under 40. Cisplatin-based combination chemotherapy
has dramatically improved the clinical outcome of patients
with metastatic non-seminomatous germ cell tumours
(NSGCTs) (Einhorn and Donohue, 1977; Horwich, 1989).
However, approximately 20% of patients with metastatic
NSGCT still die of their disease. Recently, the second
Medical Research Council (MRC) study including data
from 795 patients with metastatic NSGCT from 13 centres
defined a simple prognostic classification using four clinical
features as prognostic variables. Whereas good-risk patients
had a 3 year survival of 93%, patients with at least one ofthe
adverse features had a 3 year survival rate of 67% (Mead et
al., 1992).
The present paper analyses our single institution experi-
ence in the management of metastatic NSGCT during the
cisplatin era. The above-mentioned prognostic model is tested
on our data set, and the prognostic relevance of age is
assessed. Particular emphasis is put on whether the
substitution of etoposide for vinblastine translates into an
improved survival. Moreover, we describe the incidence of
late relapses and second malignancies.
Patients and methods
Patient characteristics
A total of 266 consecutive patients with metastatic NSGCT
underwent primary cisplatin-based chemotherapy at Klini-
kum Grosshadern between May 1979 and June 1995. Patients
with stage IIA/B were predominantly treated surgically, the
majority of whom received adjuvant chemotherapy. The
latter patient group was not included in this study; results
have been reported elsewhere (Gerl et al., 1994a).
The median age at diagnosis was 27 years (range, 16-72
years). Histology was established according to the British
Testicular Tumour Panel criteria (Pugh, 1976). No primary
histology was available in four cases, but a considerable
elevation of serum human chorionic gonadotropin (HCG)
and/or alpha-fetoprotein (AFP) indicated the presence of
NSGCT. Two patients had pure seminomas in their testicular
primaries, but high levels of HCG (both cases) and AFP (one
case) disclosed the presence of NSGCT. Prechemotherapy
staging consisted of physical examination, laboratory testing
including serum tumour marker determination, chest radio-
graph and abdominal and thoracic computerised tomography
(CT) scans. Further examinations were performed as
indicated by clinical symptoms. The characteristics of the
266 patients pertaining to the status immediately before
initiation of chemotherapy are summarised in Table L
Treatment
Up to 1983 all patients received chemotherapy according to
the PVB protocol consisting of cisplatin 20 mg m-2 on days
1-5, vinblastine 0.15-0.20 mg kg-' on days 1 and 2, and
bleomycin 30 mg on days 2, 9 and 16 (Einhorn and
Donohue, 1977). Since the end of 1983 patients with a large
tumour burden have been predominantly treated according to
the ECBC regimen consisting of etoposide 120 mg m-2 on
days 1-4, cisplatin 30 mg m-2 on days 1-4, bleomycin
15 mg on day 1 (bolus) and 12 mg m-2 on days 1-4 (24 h
infusion), and cyclophosphamide 300 mg m-2 on days 1-4
(Gerl et al., 1993). In 1987 we began to treat patients with
low-volume metastatic disease according to the PEB protocol
substituting etoposide 100 mg m-2 on days 1-5 for
vinblastine (Williams et al., 1987). Few patients received
cisplatin-ifosfamide-based chemotherapy with either vinblas-
tine (VIP) or etoposide (EIP) or other cisplatin combinations
(Table II). Patients who achieved normalisation of serum
tumour markers but had radiographic abnormalities were
alloted to adjunctive post-chemotherapy surgery. Some
patients underwent multiple surgical interventions (Gerl et
al., 1994b). The resection rate remained steady during the
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Table I Patient characteristics
Number %
Year of diagnosis
1979-83
1984-88
1989-93
1994-95
Age
<40 years
>40 years
Site of primary tumour
Testis
Retroperitoneum
Mediastinum
Histology
MTU
MTI
MTT
TD
Seminoma (marker elevated)
No histology
Stage (Royal Marsden classificationa)
IM
II
JIM
IIB
IIC
IID
III
IV
Sites of disease
Retroperitoneum
<5 cm
>5 cm, 10 cm
>10 cm
Lung
< 20 metastases
>20 metastases
Mediastinum
<5 cm
> 5 cm
Cervical nodes
Liver
Bone
Brain
95
86
71
14
240
26
229
25
12
149
77
19
15
2
4
2
56
18
12
18
8
38
170
170
52
56
62
164
119
45
58
34
24
40
27
8
8
36
32
27
90
10
86
Table H Treatment details
Number %
Chemotherapy regimens
PVB 129 48
PEB 58 22
ECBC 69 26
EIP/VIP 6
Other cisplatin combinations 4
Post-chemotherapy surgery
RPLND 101 38
Thoracotomy 60 23
Liver resection 5
Neck dissection 4
RPLND, retroperitoneal lymph node dissection. See text for other
abbreviations.
56
29
21
cancer. Patients in the category remission marker negative
(Rm-) showed at least no progression in all measurable sites
of tumour and normalisation of serum tumour markers for at
least 4 weeks. Progressive disease before or within 4 weeks
after discontinuation ofchemotherapy or a response less than
a Rm- were regarded as primary treatment failures.
Follow-up
14 Patients underwent clinical, radiological and biochemical
64 examinations at 3 months during the first 2 years and at 6
month intervals during the third year, thereafter annually.
64 The majority of patients (83%) was monitored at Klinikum
Grosshadern. The follow-up status of the remaining 17% of
patients was verified by contact with the patients and their
r,1) primary physicians. No patient was lost for follow-up.
22
Tumour markers
AFP elevated (> 15 ng ml-) 162 61
<1000 ng ml-' 104
>I000ngml-' 58
HCG elevated (> 5 IU 1-1) 172 64
<10000 IU 1-1 121
>10000oIU 1i 50
MTU, malignant teratoma undifferentiated; MTI, malignant
teratoma intermediate; MTT, malignant teratoma trophoblastic; TD,
teratoma differentiated. aSee Dearnaley et al. (1991); IM, marker
elevation only after orchidectomy; IIB, C, D, retroperitoneal disease
<5, 10, > 10 cm respectively; IIM, marker elevation only after
retroperitoneal lymph node dissection; II, supradiaphragmatic lymph
node involvement; IV, visceral metastasis.
entire time span (Gerl et al., 1995a). Few patients with
chemorefractory but localised disease that was deemed
resectable were also alloted to post-chemotherapy surgery
(Gerl et al., 1995b). The type and number of surgical
interventions are summarised in Table II.
Evaluation of response
Complete response 1 (CR1) was defined as total disappear-
ance of clinical, radiological and biochemical signs of disease
for at least 4 weeks. Patients who had a complete resection of
residual masses containing only necrosis/fibrosis or mature
teratoma also qualified for CR1. CR2 was defined as
disappearance of disease after complete resection of viable
Statistical analysis
Survival was measured from the date of commencement of
chemotherapy- Survival curves were constructed using the
Kaplan-Meier method (Kaplan and Meier, 1958), and
comparative survival of subgroups was determined by the
log-rank test (Mantel and Haenszel, 1959). All variables
achieving a log-rank P-value of less than 0.05 were included
in a multivariate analysis to identify independent prognostic
factors. Cox's proportional hazards regression model
(Tibshirani, 1982) was used with the statistical package
BMDP (Dixon, 1990) and a forward stepwise selection
procedure. All P-value statistics quoted are on 1 d.f., unless
otherwise stated.
Results
Response and survival
A total of 205 patients (77%) achieved a CR, 11 patients
(4%) a Rm- (Table III). Primary treatment failure occurred
in 37 patients (14%). Response could not be assessed in six
patients, who died within 2 months from start of
chemotherapy. Seven patients (2.6%) died owing to
chemotherapy-related toxicity: three as a result of neutro-
penic septicaemia, two owing to bleomycin-induced pulmon-
ary toxicity, and two due to cerebral infarction.
Median follow-up time of surviving patients was 93
months (range, 6-193 months). Follow-up of 2 years was
available in 91% of patients, and 83% of patients were
observed for at least 3 years. Altogether 32 patients (16%)
relapsed from a CR, 12 of whom are currently alive with no
evidence of disease (NED) status. Nine of the 32 recurrences
were late relapses, since they occurred after a disease-free
interval of more than 2 years. Five further patients developed
a late relapse from a second CR or a Rm-. Twelve ofthe 14
patients with late relapses had received PVB as primary
chemotherapy.Metastatic non-seminomatous germ cell tumours
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Table III Response to treatment and outcome
Number %
Response
CR 205 77
CR1 190
CR2 15
Rm- 11
Primary treatment failure 37 14
Dead due to toxicity 7
Early death, response not assessable 6
Current status
Alive NED 182 68
Alive with Rm- 8
Alive with disease 4
Dead due to germ cell tumour 69 26
or treatment-related toxicity 2
Dead due to second cancer 1
Dead due to unrelated cause
See text for abbreviations.
Three patients with tumours of retroperitoneal origin
developed a testicular seminoma at 35, 42 and 77 months, all
of whom are currently disease-free. Two patients with
testicular primaries developed a tumour of the contralateral
testicle at 56 and 91 months; histology was seminoma in one
case and non-seminoma in the other; both patients are
currently alive with NED status.
Two patients developed non-germ cell malignancies on
follow-up. One of these patients, who had been treated
according to the PVB schedule, died from non-Hodgkin's
lymphoma at 38 months; an association between germ cell
tumour chemotherapy and the second malignancy seems
uncertain. The second patient developed a glioblastoma 115
months after whole brain irradiation for a cerebral relapse
and died 11 months later; a relation between radiotherapy
and the second cancer seems probable. A total of 119
surviving patients had received etoposide as part of their
primary or salvage treatment, in 31 of whom (26%) the
cumulative dose exceeded 2000 mg m-2. After a total of 612
patient-years of observation none of the 119 patients
developed a secondary leukaemia.
One patient in CR died due to a car accident at 164 months;
this death was considered as a censoring event. In the final
evaluation, 182 patients (68%) were alive with NED status,
eight were alive with negative markers and stable residual
masses (Rm-), and four were alive with disease. In all, 69
patients (26%) died owing to toxicity or uncontrolled germ cell
malignancy, two patients due to second neoplasms (Table III).
Some 56% of deaths occurred during the first year from the
date ofcommencement ofchemotherapy, 82% during thefirst 2
years, and 85% during the first 3 years. Nine deaths (13%),
eight caused by late relapse from germ cell tumour and one due
to second malignancy, occurred more than 5 years from start of
chemotherapy. All nine patients had received their primary
chemotherapy according to the PVB protocol. The latest death
from germ cell tumour was at 138 months. The overall 3 year
survival was 77% [95% confidence interval (CI) 72 -82%], and
3 year progression-free survival was 71% (95% CI 65-77%).
Prognostic factors
Univariate analysis of prognostic variables is summarised in
Table IV. The 5 year period of diagnosis reached borderline
significance (P =0.047, 2 d.f.). Comparing the period 1979 -83
with the period 1984-88, 3-year survival increased only
modestly from 71% to 74%; the difference was not significant
(P= 0.6). Patients treated during the period 1989-93 attained
a 3-year survival of 87%, which was significantly better
(P =0.046) than the survival of patients treated in the period
1984-88.
Of the patient characteristics, tumour origin (testicular
vs extragonadal) reached prognostic relevance. The following
Table IV Prognostic factors-univariate comparisons
3-year
survival 95% CI
Prognostic variable No. (%) (%) P
Period of diagnosis
1979-83 95 71 61-80
1984-88 86 74 65-84 0.047
1989-93 71 87 79-95 (2 d.f.)
Age
<40 years 240 78 72-82
>40 years 26 69 51-87 0.309
Site of primary tumour
Testicular 229 80 74-85
Extragonadal 37 61 45-78 0.009
Tumour markers
Low markers 166 85 80-91
High markers 100 64 54-73 <0.0001
Liver, bone or brain
metastases
No 230 84 79-89
Yes 36 35 19-52 <0.0001
Twenty of more lung
metastases
No 221 83 77-88
Yes 45 49 34-64 <0.0001
Mediastinal mass >5 cm
No 242 79 74-85
Yes 24 54 34-75 0.0005
Type of chemotherapy
Vinblastine 132 71 63 -79
Etoposide 134 83 77-90 0.017
patient characteristics predicted a poor outcome: high
serum tumour markers (HCGO 10000 IU 1-1 and/or
AFP ) 1000 ng ml-1), a mediastinal mass greater than 5 cm,
the presence of liver, bone or brain metastases, and the
presence of 20 or more lung metastases. In contrast, age at
diagnosis was not a significant prognostic factor: patients
over the age of40 years had a 3-year survival of69% compared
with 78% for the younger patients (P =0.3). Patients receiving
etoposide-containing chemotherapy had a significantly im-
proved survival compared with patients treated according to
vinblastine-containing protocols (Table IV).
All clinical variables achieving a significance level less than
0.05 on log-rank test were included in the multivariate
analysis. Four pretreatment variables entered the model in
the same order as in the second MRC study: the presence of
liver, bone or brain metastases, high serum tumour marker
levels, the presence of a mediastinal mass greater than 5 cm,
and the presence of 20 or more lung metastases (Table V). A
total of 124 patients (47%) had at least one of these poor risk
factors; the 3-year survival of this patient group was 61%
(95% CI 53-70%) compared with 91% (95% CI 86-96%)
for the patients with no poor risk factor (Figure 1). Survival
according to the number of poor risk features is shown in
Figure 2 and Table VI. Seven of the nine patients who died
due to malignancy more than 5 years after commencement of
chemotherapy belonged to the poor risk group.
The proportion of poor risk patients remained almost
steady during the entire time span of study: 45% in the
period 1979-83, 48% in the periods 1984-88 and 1989-93.
Furthermore, the proportion of poor risk patients was similar
in patients over the age of 40 (42%) as in younger patients
(47%).
Apart from the four above-mentioned clinical features,
multivariate analysis identified etoposide-containing che-
motherapy as an independent predictor of favourable out-
come. Whereas good risk patients had an identical 3-year
survival rate of 91% regardless of vinblastine- or etoposide-
containing chemotherapy, etoposide-containing protocols
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Table V Multivariate analysis
Hazards
Step variable Chi-square P ratio 95% CI
1 Liver, bone or
brain metastases 31.3 <0.0001 3.4 1.9-6.2
11.9 0.001 2.4 1.4-4.1
2 Marker
3 Etoposide-containing 12.8 <0.001 0.35 0.2-0.6
chemotherapy
4 Size of mediastinal 7.3 0007 2.4 1.3-4.7
mass
5 No. of lung 6.2 0.013 2.0 1.2-3.5
metastases
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Figure 3 Survival of poor risk patients by type ofchemotherapy:
1, etoposide-containing; 2, vinblastine-containing. In brackets: the
number of patients that remain at risk at 40, 80 and 120 months.
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Figure 1 Survival from the beginning of chemotherapy by
prognostic group: 1, no poor risk factor; 2, any of the adverse
features.
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Figure 2 Survival by number of poor risk factors: 1, none; 2, any
one; 3, any two; 4, any three or all four.
considerably improved survival in poor risk patients
(P<0.0001). The 3-year survival rate was 76% (95% CI 66-
87%) for poor risk patients receiving etoposide compared with
45% (95% CI 31-58%) for poor risk patients receiving
vinblastine (Figure 3). Of 68 poor risk patients receiving
etoposide-containing chemotherapy, 55 (81%) were treated
according to the ECBC protocol. The proportion of poor risk
patients receiving etoposide-containing chemotherapy was 5%
in 1979-83, 63% in 1984-88 and 100% in the period 1989-
93.
Discussion
The incidence of 2.6% for treatment-related deaths is lower
than in a large multicentre trial (Williams et al., 1987). It is
Table VI Survival by number of poor-risk features
3-year S-year
survival survival
No. (%) 95% CI (%) 95% CI
None of the features
('good risk') 142 91 87-96 91 87-96
Any one of the four 61 73 62-85 71 60-83
Any two of the four 47 61 46-75 58 43-73
At least three of the 16 19 0- 38 19 0-38
four
worthwhile mentioning two cases of fatal cerebral infarction.
The young age of the patients and a close temporal
association to the administration of chemotherapy argued
against coincidence. The incidence of major vascular events
following chemotherapy of germ cell tumours has been
reviewed elsewhere (Gerl, 1994).
With our relatively large data set of patients with
metastatic NSGCT treated at a single institution during the
cisplatin era we could confirm the validity of the prognostic
model which was suggested by the second MRC study
(Mead et al., 1992). It is of note that even the order of
prognostic factors was identical. The presence of liver, bone
or brain metastases was the most adverse feature, followed
by high levels of serum tumour markers, a mediastinal mass
greater than 5 cm, and by the presence of 20 or more lung
metastases.
In contrast to the second MRC study and to another
recent report (Aass et al., 1991), we could not confirm the
prognostic relevance of age. Three year survival was slightly
inferior in the older patients, but probably owing to the
relatively small number of patients over 40 years, the
difference did not reach statistical significance. A recent
population-based study from Scotland also could not confirm
the prognostic relevance of age (Hatton et al., 1995). In
contrast, we found that age was a prognostic factor in
patients with recurrent or refractory germ cell tumours
undergoing salvage treatment (Gerl et al., 1995b).
Only 14% of the patients included in the second MRC
study did not receive etoposide as a component of their
treatment. This small proportion ofpatients was not found to
carry an inferior prognosis compared with the remaining
patients (Mead et al., 1992). In contrast, we showed that
etoposide-containing chemotherapy was an independent
predictor of favourable long-term outcome. However, it is
of note that good risk patients had an identical 3-year
survival of 91% regardless of etoposide- or vinblastine-
n-0a0c% germ A Geri et i
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containing chemotherapy. In poor risk patients etoposide-
including regimens led to a 3-year survival rate of 76% as
compared with 45% for vinblastine-containing chemother-
apy. These results apparently are in concordance with the
report ofanother study group which described the superiority
of etoposide compared with vinblastine in an otherwise
identical protocol for patients with poor risk metastatic
disease (Williams et al., 1987). However, our comparison
should be interpreted with caution, as 81% of poor risk
patients receiving etoposide were treated according to a four
drug regimen which additionally included cyclophosphamide;
moreover, the cisplatin dose was 20% higher than in
standard protocols. Thus, the intensity of chemotherapy
may also have had a confounding effect on our results. A
recent report on a non-randomised clinical trial suggested
that dose-intensive chemotherapy may translate into im-
proved survival in poor prognosis patients (Bokemeyer et al.,
1995b). Furthermore, there is some evidence that results in
poor risk disease improve with an increasing number of
treated patients (Aass et al., 1991). Considering the
observational nature of the data, our analysis may over-
estimate the contribution of etoposide.
During recent years some reports raised concern with
regard to the risk of secondary leukaemia in germ cell
tumour patients treated with etoposide-containing che-
motherapy (Pedersen-Bjergaard et al., 1991; Nichols et al.,
1993; Bajorin et al., 1993; Boshoff et al., 1995). However, this
risk appears to be low (approximately 0.5%) in patients
receiving standard doses of etoposide. In contrast to the first
report (Pedersen-Bjergaard et al., 1991), a recent report
(Bokemeyer et al., 1995a) suggested that this risk may even
be low in patients receiving cumulative doses of etoposide of
more than 2000 mg m-2. Our long-term results also argue in
favour of a low risk, since no case of secondary leukaemia
was observed after 612 patient-years of observation.
Therefore, the benefit of etoposide-containing chemotherapy
outweighs the risk of secondary leukaemia in poor risk
patients, whereas non-etoposide-containing protocols may be
considered in good risk patients (Boshoff et al., 1995).
Overall, the risk of second cancer related to germ cell
tumour therapy appears to be low. We observed only two
cases of non-germ cell malignancies, and only in one of these
cases a causative relationship between whole brain irradiation
for cerebral relapse and the development of a glioblastoma
almost 10 years later seemed probable. Five of our patients
(2%) developed a second germ cell tumour on follow-up,
underscoring that this risk is not eliminated by chemotherapy
(Fossa and Aass, 1989). Four ofthese patients presented with
stage I disease and were treated by orchidectomy alone, while
the fifth patient had stage H disease and underwent a second
chemotherapy. All five patients are currently alive and
disease-free.
It is of note that nine of 32 relapses from complete
remission occurred after a disease-free interval ofmore than 2
years. A further five patients developed a late relapse from a
second complete response or from a marker-negative
response. Twelve of the 14 patients with late relapses had
received PVB as primary chemotherapy. As in a recent report
(Baniel et al., 1995), long-term outcome of patients with late
relapses was poor. Eight of the 14 patients ultimately died of
their disease, and one is alive with uncontrolled malignancy.
Although, in agreement with the second MRC study (Mead
et al., 1992), 85% of deaths due to germ cell tumour were
observed within 3 years from commencement of chemother-
apy, the occurrence of late relapses emphasises the need to
report long-term results (Hitchins et al., 1989; Dearnaley et
al., 1991). Possibly the incidence of late relapses is lower in
patients receiving etoposide-containing chemotherapy as
suggested by a recent report (Dearnaley et al., 1991), but
our results do not allow for definite conclusions, since median
follow-up in this subgroup is only 53 months. In contrast,
patients receiving PVB have all passed through a follow-up
period of 8 years in which the majority of late relapses may
occur. In a recent report time to late relapse ranged from 2 to
32 years, with a median of 6.2 years (Baniel et al., 1995).
It is ofnote that treatment results improved only modestly
between 1984 and 1988 compared with the period 1979-83,
as only 5% of poor risk patients received etoposide during
1979-83 compared with almost two-thirds in the following 5
year period. A more pronounced improvement in survival
occurred between 1989 and 1993. Therefore, other factors
than the inclusion of etoposide may be operative. Some
reports suggested that it is the cumulative experience in
pathology, surgery, radiology and biochemistry, in addition
to that of the oncology staff, that leads to improved survival
in specialist referral centres (Einhorn, 1986; Aass et al., 1991;
Harding et al., 1993; Feuer et al., 1994; Howard et al., 1995).
A recent review suggested that centralised treatment may
improve survival in cancer patients (Stiller, 1994). Unfortu-
nately, we are not able to compare our results with
population-based data, as Germany does not have a national
cancer registry at present. However, one report studying the
mortality from testicular cancer between 1979 and 1989
described a more rapid decrease in Munich than in the rest of
the Federal Republic (Hoelzel and Altwein, 1991). Never-
theless, there is a trend of decentralisation of treatment of
testicular cancer in Germany as shown by a slightly
decreasing referral rate to our centre.
In conclusion, the analysis of our single institution data
confirms the validity of the prognostic model that was
suggested by the second MRC study. However, we could not
find a prognostic significance of age. Cumulative experience,
intensified therapy and the use of etoposide-containing
chemotherapy regimens led to a marked improvement of
long-term survival in patients with poor risk metastatic
disease. The incidence of second non-germ cell malignancies
is very low at present, but the observation time is too short to
exclude an increase of solid tumours. The relatively high
incidence of late relapses emphasises the need to report long-
term results.
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